CONTACT US
Home > Reference Standards> > Mafosfamide Sodium Salt
84211-05-2-Mafosfamide Sodium Salt Mafosfamide Sodium Salt

Mafosfamide Sodium Salt

For research use only. Not for therapeutic Use.

  • CAT Number: R011922
  • CAS Number: 84211-05-2
  • Molecular Formula: C₉H₁₈Cl₂N₂NaO₅PS₂
  • Molecular Weight: 423.25
  • Purity: ≥95%
Inquiry Now
Related Small Molecules: (1-TRITYL-1H-IMIDAZOL-4-YL)METHYL ACETATE     5(6)-Carboxytetramethylrhodamine succinimidyl ester     2,3,4,5-Tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepine    

<p>
Mafosfamide Sodium Salt (CAS&nbsp;84211-05-2)&nbsp;<span style="font-family:arial,helvetica,sans-serif;"><span style="font-size:12px;"><span style="font-variant-ligatures: normal; orphans: 2; widows: 2;">&nbsp;<span style="font-variant-ligatures: normal;">is a cyclophosphamide analog that induces apoptosis and acts as an antitumor agent in vitro.&nbsp;</span></span></span></span><span style="orphans: 2; widows: 2; font-family: arial, helvetica, sans-serif;">It alkylates DNA, forming DNA cross-links and inhibiting DNA synthesis.&nbsp;</span></p>


Catalog Number R011922
CAS Number 84211-05-2
Synonyms

rel-2-[[(2R,4R)-2-[Bis(2-chloroethyl)amino]tetrahydro-2-oxido-2H-1,3,2-oxazaphosphorin-4-yl]thio]ethanesulfonic Acid Sodium; Mafosfamid Sodium; Z 7557; cis-Mafosfamide Sodium;

Molecular Formula C₉H₁₈Cl₂N₂NaO₅PS₂
Purity ≥95%
Storage -20°C
IUPAC Name sodium;2-[[(2R,4R)-2-[bis(2-chloroethyl)amino]-2-oxo-1,3,2$l^{5}-oxazaphosphinan-4-yl]sulfanyl]ethanesulfonate
InChI InChI=1S/C9H19Cl2N2O5PS2.Na/c10-2-4-13(5-3-11)19(14)12-9(1-6-18-19)20-7-8-21(15,16)17;/h9H,1-8H2,(H,12,14)(H,15,16,17);/q;+1/p-1/t9-,19-;/m1./s1
InChIKey LHXWPBHSZFEANP-KCPSBDNSSA-M
SMILES C1COP(=O)(NC1SCCS(=O)(=O)[O-])N(CCCl)CCCl.[Na+]
Reference

<p>
<span style="font-family:arial,helvetica,sans-serif;"><span style="font-size:12px;"><span style="font-variant-ligatures: normal; orphans: 2; widows: 2;">1. Miller, CR. et al. 2017. Oncotarget. 8: 25942-25954. PMID: # 28412730</span><br style="box-sizing: border-box; color: rgb(51, 51, 51); font-family: openSans, arial, sans-serif; font-size: 14px; font-variant-ligatures: normal; orphans: 2; widows: 2;" />
<span style="font-variant-ligatures: normal; orphans: 2; widows: 2;">2. Ninomiya, S. et al. 2015. Blood. 125: 3905-16. PMID: # 25940712</span><br style="box-sizing: border-box; color: rgb(51, 51, 51); font-family: openSans, arial, sans-serif; font-size: 14px; font-variant-ligatures: normal; orphans: 2; widows: 2;" />
<span style="font-variant-ligatures: normal; orphans: 2; widows: 2;">3. Klaus, CR. et al. 2014. The Journal of pharmacology and experimental therapeutics. 350: 646-56. PMID: # 24993360</span><br style="box-sizing: border-box; color: rgb(51, 51, 51); font-family: openSans, arial, sans-serif; font-size: 14px; font-variant-ligatures: normal; orphans: 2; widows: 2;" />
<span style="font-variant-ligatures: normal; orphans: 2; widows: 2;">4. Knutson, SK. et al. 2014. PloS one. 9: e111840. PMID: # 25493630</span><br style="box-sizing: border-box; color: rgb(51, 51, 51); font-family: openSans, arial, sans-serif; font-size: 14px; font-variant-ligatures: normal; orphans: 2; widows: 2;" />
<span style="font-variant-ligatures: normal; orphans: 2; widows: 2;">5. Kikuchi, K. et al. 2014. PLoS genetics. 10: e1004107. PMID: # 24453992</span><br style="box-sizing: border-box; color: rgb(51, 51, 51); font-family: openSans, arial, sans-serif; font-size: 14px; font-variant-ligatures: normal; orphans: 2; widows: 2;" />
<span style="font-variant-ligatures: normal; orphans: 2; widows: 2;">6. Burgess, M. et al. 2013. Clinical cancer research : an official journal of the American Association for Cancer Research. 19: 5675-85. PMID: # 23948971</span></span></span></p>

Request a Quote